Granite Point Capital Management L.P. continued to hold its position in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,000 shares of the biotechnology company’s stock at the close of the 2nd quarter. Granite Point Capital Management L.P. owned 0.11% of Five Prime Therapeutics worth $903,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. BB Biotech AG acquired a new position in shares of Five Prime Therapeutics during the 1st quarter valued at $26,299,000. Renaissance Technologies LLC acquired a new position in shares of Five Prime Therapeutics during the 1st quarter valued at $16,734,000. MARSHALL WACE ASIA Ltd acquired a new position in shares of Five Prime Therapeutics during the 1st quarter valued at $10,272,000. Marshall Wace North America L.P. acquired a new position in shares of Five Prime Therapeutics during the 1st quarter valued at $10,272,000. Finally, State Street Corp lifted its position in shares of Five Prime Therapeutics by 25.7% during the 1st quarter. State Street Corp now owns 1,249,520 shares of the biotechnology company’s stock valued at $45,175,000 after acquiring an additional 255,488 shares during the period. 84.08% of the stock is currently owned by institutional investors.

FPRX has been the topic of a number of research reports. ValuEngine upgraded shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Jefferies Group LLC reiterated a “buy” rating and set a $52.00 target price on shares of Five Prime Therapeutics in a research report on Tuesday. Finally, BidaskClub downgraded shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $60.80.

ILLEGAL ACTIVITY WARNING: “Granite Point Capital Management L.P. Has $903,000 Holdings in Five Prime Therapeutics, Inc. (FPRX)” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/09/14/granite-point-capital-management-l-p-has-903000-holdings-in-five-prime-therapeutics-inc-fprx.html.

Five Prime Therapeutics, Inc. (NASDAQ FPRX) traded down 1.64% on Thursday, reaching $34.87. 29,833 shares of the company’s stock traded hands. The company’s market cap is $975.84 million. The firm’s 50 day moving average price is $30.27 and its 200 day moving average price is $32.37. Five Prime Therapeutics, Inc. has a 12 month low of $25.97 and a 12 month high of $60.98.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.43). The company had revenue of $7.80 million during the quarter, compared to the consensus estimate of $8.32 million. Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The business’s revenue was down 16.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.49) EPS. On average, equities analysts expect that Five Prime Therapeutics, Inc. will post ($5.16) EPS for the current fiscal year.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics, Inc. (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.